Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

FILE - The Pfizer logo is displayed at the company's headquarters, Friday, Feb. 5, 2021, in New York. (AP Photo/Mark Lennihan, File)

NEW YORK (AP) — U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss treatments Ozempic and Wegovy.

Metsera, based in New York, has no products on the market, but it is developing oral and injectable treatments. That includes some potential treatments that could target lucrative fields for obesity and diabetes.

The ɫtv Press. All rights reserved.

More Health Stories

Sign Up to Newsletters

Get the latest from ɫtvNews in your inbox. Select the emails you're interested in below.